DANAHER CORP /DE/
DANAHER CORP /DE/ (DHR) Stock News
The latest DHR headlines and market coverage — 2 recent stories, updated throughout the day.
- Zacks Investment Research·
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
Danaher (DHR) is positioned as a likely earnings beat candidate for Q3 2026 with an Earnings ESP of +0.30% and Zacks Rank #2 (Buy). The company is expected to report EPS of $1.92 (up 1.6% YoY) and revenues of $6.55 billion (up 8.2% YoY). With a history of beating consensus estimates in the last four quarters, the stock appears well-positioned for positive price movement following its October 21 earnings release.
- Zacks Investment Research·
ELV or DHR: Which Is the Better Value Stock Right Now?
In a comparison of two Medical Services stocks, Elevance Health (ELV) emerges as the superior value option over Danaher (DHR). ELV holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 15.70 and PEG ratio of 2.22. DHR has a Zacks Rank of #3 (Hold) with a Value grade of D, with a forward P/E of 23.84 and PEG ratio of 2.53. Based on valuation metrics and earnings outlook, ELV is positioned as the better value investment.